HDAC3 and plasma cell myeloma: Combined HDAC3 inhibitor and AZA, a DNMT1 inhibitor, was found to synergistically downregulate DNMT1, resulting in the growth inhibition and apoptosis of MM cell lines and myeloma patient-derived cells [51].